Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
NCT05631262Phase 2Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma (NPC) (7 arms), sponsored by Kelun-Biotech. Primary endpoints: Objective Response Rate and Incidence and severity of adverse events. Started Nov 2022; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05631262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631262.